The FDA has approved Samsung Bioepis’ Renflexis (infliximab-abda), a biosimilar referencing Remicade i (infliximab), across all eligible indications. In the U.S., Renflexis is indicated for reducing signs and symptoms in patients with adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis. It is the first Samsung Bioepis product approved for marketing in the U.S.. “Sin...